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ABSTRACT
Current COVID 19 outbreak is a critical issue in safeguarding public health worldwide. The lack of prophylactic 
drugs, vaccine and effective antiviral and other supporting therapies has prompted researchers to look for promising 
leads against the virus. Metabolic pathways and biochemicals involved in pathophysiology of SARS-CoV-2 can 
be targeted to find out effective inhibitor molecules acting at the entry point of infection. SARS-CoV-2 uses their 
Spike protein to dock at ACE2 and the serine protease, TMPRSS2 of host cell for Spike protein priming to get entry 
into the host cell. In the present study phytochemicals from Zingiber officinale were evaluated to find their binding 
with these proteins by conducting ligand-receptor binding docking study with AutoDockVina. The structures were 
observed by visualizing softwares Pymol to determine unique amino acids of receptor proteins. Physicochemical 
properties of phytochemicals and chemotherapeutic markers were assessed with Molinspiration tool. Docking study 
revealed that Gingerenone (-5.87 kcal/mol) and Zingiberene (-5.77 kcal/mol) have shown effective binding affinity 
towards ACE2. Shoagol (-5.72 kcal/mol), Zingerone (-5.79 kcal/mol) and Zingiberene (-5.52 kcal/mol) have shown 
higher binding with extracellular domain of serine protease TMPRSS2. Zingiberene scored significant binding energy 
of  -6.23 kcal/mol with Spike protein of SARS-CoV-2. This study provides an evidence base to the experiential 
learning about use of Zingiber officinale in microbial infections. Once further validated, it may lead to development 
of herbal based anti-viral adjuvants.
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1. INTRODUCTION
COVID-19 is a coronavirus disease caused by 2019 
novel corona virus now called as SARS-CoV-21. SARS-
CoV-2 is very significant and dreadful virus of Coronavirinae 
subfamily from Coronaviridae family2,3. Coronaviridae have 
been drawing attention globally since last two decades as its 
important members severe acute respiratory syndrome (SARS-
CoV) (2002-2004) and middle east respiratory syndrome 
(MERS-CoV) (2012, 2015 and 2018), are intermittently 
causing pneumonia a respiratory syndrome4. SARS-CoV-2 
confirmed by Chinese health authorities as an etiological agent 
for cluster of pneumonia cases in Wuhan, China in December 
20195. The bushfire effect of COVID-19 compelled World 
Health Organisation (WHO) to declare it a Pandemic on 11th 
March 20206. The epidemic, which started out from Wuhan, 
China now spread to 214 Countries and Territories around 
the world with a total of 3,60,41,783 confirmed cases and a 
death toll of 10,54,604 deaths  as on 7th October 20207-9. Fever, 
non-productive cough, dyspnea, myalgia, fatigue, imbalance 
in leukocyte counts and radiographic evidence of pneumonia 
are the important clinical symptoms of COVID-1910. In 
worsening dyspnea ventilator support is required. This may 
result in another threat of secondary nosocomial infections, 
such as ventilator-associated pneumonia11. Combination of 
antibacterial and antiviral therapy is being given to the COVID 
patients12. WHO has initially approved the drug chloroquine 
and hydroxychloroquine trial in “Solidarity trial” for the 
management of COVID-1913.
There is a need to identify novel potential inhibitor for 
SARS-CoV-2 that can control the pathology by targeting 
its mechanism of infection. SARS-CoV-2 utilises its Spike 
protein as a significant part of its envelop that participate in 
the interaction with its cellular receptor angiotensin converting 
enzyme 2(ACE2)14. Consequently, the spike protein is cleaved 
by extracellular catalytic domain of Transmembrane protease 
Serine 2 (TMPRSS2) also called as Serine protease or Hepsin15 
leading to entry of virus into the host cell16. Therefore, the 
cascade involved in the attachment and entry of SARS-CoV-2 
virus is the most crucial step of pathogenesis mediated by 
Spike protein, ACE2 and further assisted by extracellular 
catalytic domain of TMPRSS2 on cell membrane. Inhibition 
of these steps may lead to the design of promising drug targets 
for COVID-19.Chloroquine has its root in herbal medicine 
as it is an analogue of quinine isolated from bark extract of 
Cinchona officinalis17. Mother nature treasures many such 
molecules that can be used as prophylactic, and adjunct 
to therapeutic approaches. The exploration of herbals for 
potential prophylactic and therapeutic utility requires a logical 
interface, that is, in silico study for screening or selection of 
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active phytoconstituents. The natural plant products provide an 
excellent resource for discovering novel antiviral agents with 
the help of shape based superposing docking. Current progress 
in computational methods can be helpful in selection of probable 
agents or repurposing licensed drugs18. Drug repurposing, 
meant drug discovery procedure from existing medications, 
could altogether abbreviate the time and diminish the expense 
contrasted with a new drug revelation and randomised clinical 
preliminaries18. However the drug repurposing is costly and 
time-consuming. Computational methodologies offer novel 
testable theories for methodical medication repositioning19.
The Zingiber officinale is reported to be effective against 
respiratory ailments. Z. officinale has been proved to be loaded 
with ethnopharmalogical properties including the inhibition 
of ACE20. Also, it is reported to exhibit antibacterial, anti-
biofilm and cell permeability activities in case of pneumonia 
induced by Pseudomonas aeruginosabacteria21, which is a 
major cause of ventilator-associated pneumonia21. The fresh 
and dried Z. officinale extract have also been shown to possess 
anti-viral activity against human respiratory syncytial virus 
and Chikungunya virus as tested in different cell lines22,23. In 
majority of the herbal drugs, the crude or semipurified extracts 
are generally superior to the isolated phytochemicals in terms of 
bioactivity as the phytochemical constituents act synergistically. 
However, for establishing the molecular mechanism of action, 
studies are carried out on isolated moieties. In the present study 
it is planned to explore the point of action of major constituents 
of Z. officinale against SARS-CoV-2. Major phytochemicals of 
Ginger showing following activities have been selected for the 
ligand-receptor binding docking study. Zingiberene, Shoagol, 
Gingerdione and Gingerol, are known to obstruct reverse 
transcriptase enzyme and thereby inhibits viral replication24. 
Zingerone improves cellular and humoral immune response 
in viral infection25. Gingerenone is known to possess anti-
hypercholesteremic effect and has been included as the patients 
with familial hypercholesterolemia (FH) are at very high 
risk of cardiovascular disease, which is associated with poor 
outcomes from coronavirus infections26,27. The present in silico 
study was performed mainly to find out potential inhibitors for 
entry of the SARS-CoV-2 virus into the host cell by targeting 
ACE2, Spike protein, and extracellular domain of hepsin as 
components of virus-host protein interaction. The binding 
score were compared with the selected chemotherapeutic 
marker drugs like chloroquine and hydroxychloroquineas 
that are reported to be a potent inhibitor of SARS coronavirus 
infection by binding with ACE2 receptor11,12. The aim is to 
explore the major phytochemicals of Z. officinale to select the 
promising ones that can work holistically at entry point of the 
virus. Another objective was also to assess the drug-likeness 
properties of each ligand.
2. MATERIALS AND METHODS
2.1 Softwares
The present in silico study was a combination of different 
web servers and operating system that were used to accomplish 
individual step including Pubchem(http://pubchem.ncbi.
nlm.nih.gov/)22, RCSb Protein Data bank (https://www.rcsb.
org/)23, Protein Data bank Japan (https://www.pdbj.org/)28, 
Open babel (https://protein.plus)29 Molinspiration (https://
www.molinspiration.com/)30, online SMILES translator and 
structure file generator (https://cactus.nci.nih.gov/translate/)31, 
MGL tool 1.5.632, Autodock Vina32, and Pymol 2.3.432.
2.2 Host-Viral Proteins, Phytochemicals and 
Chemotherapeutic Marker Drugs 
Angiotensin converting enzyme 2 (PDb ID: 1R42; 
native human angiotensin enzyme-related carboxypeptidase)33 
were studied in silico by downloading their structures 
from RCSb Protein Data bank, Serine protease hepsin 
(TMPRSS2) 2-{5-[Amino(Iminio)Methyl]-1H-benzimidazol-
2-yl}benzenolate (PDb ID: 1P57; Extracellular Domain of 
Hepsin) was downloaded from Protein Data bank Japan34, 
SARS-CoV-2 Spike ectodomain structure (PDb ID: 6Vyb) 
was retrieved from RCSb Protein Data bank35. Structures 
of the phytochemicals of Z. officinale namely Zingiberene 
(PubChem CID: 92776), Zingerone (PubChem CID: 31211), 
Shoagol (PubChem CID: 5281794), Gingerenone (PubChem 
CID: 5281775), 1-Dehydro- 6-gingerdione (PubChem CID: 
139031793), and Gingerol (PubChem CID: 442793) were 
obtained from Pubchem. Chloroquine(PubChem CID: 2719), 
hydroxychloroquine (PubChem CID: 3652) and Camostat 
mesylate (PubChem CID: 5284360) were selected from 
the list of WHO “Solidarity” clinical trial programme as 
chemotherapeutic markers13 and their structures were taken 
from Pubchem.
2.3 Assessment of Ligands for Drug Likeliness
Virtual screening of ligands by using Molinspirationan 
online property calculation toolkitfor drug likeliness was 
performed check violation from ‘Lipinski rule of 5’ on the basis 
of physicochemical properties including MiLog P, molecular 
weight, number of atoms, number of hydrogen bond donors 
and acceptors and number of rotatable bonds. Ligands were 
loaded in the Molinspiration software with SMILES as an 
input and the calculation of their physicochemical properties 
were conducted as per ‘Lipinski rule of 5’38.
2.4 In silico Screening 
2.4.1 Preparation of Receptors and Ligands
The pdb structure of ACE2, SARS-CoV-2 Spike 
ectodomain structure, and extracellular domain of Hepsin 
protein/Serine protease TMPRSS2 were retrieved from RCSb 
PDb or other databanks as applicable. The pdb structure was 
than converted into pdbqt readable file format in the AutoDock 
Tools 1.5.632.
The ligands first converted into SMILES file format 
from sdf file format by using OpenBabel GUI. The SMILES 
file format for each ligand than converted into pdb structure 
by using online SMILES translator and structure file 
generator (https://cactus.nci.nih.gov/translate/)31. The pdb file 
format then converted into pdbqt readable file format in the 
AutoDockTools(ADT)4.232.
The pdbqt file format of receptors and ligands further 
converted into grid and docking parameter file (a.gpf and 
a.dpf) using ADT4.232.
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4.2.2 Molecular Docking
Molecular docking was carried out by using AutoDock 
Vina32. Three different set of docking studies were performed 
with six phytoligands from Z. officinale respectively: the 
first set for ACE2; the second set for SARS-CoV-2 Spike 
ectodomain structure and the third set was for extracellular 
domain of Hepsin protein/Serine protease TMPRSS2. The 
chemotherapeutic agonists were also docked as positive 
control set. The receptor grid generation was done by using 
receptor grid generation panel for all the three receptors. Grid 
box spacing was0.889A°, 1.000A° and 0.497A° for ACE2, 
Spike protein and Serine protease hepsin, respectively in order 
to cover almost whole binding pocket and its adjacent residues. 
Lamarckian Genetic Algorithm (GA) in combination of grid 
based energy evaluation method was used for docking. The 
program was run for a total number of 10 Genetic algorithm 
runs. The ligand moved around the rigid protein 25,000,000 
energy evaluations for each cycle. Other parameters were set 
as default. The visualizing was done with the Pymol 2.3.4 
software.
 
3. RESULTS 
3.1 Ligands Scanning for Drug Likeliness
Gingerol, Zingiberene, Zingerone, Gingerenone, 
1-dehydro,6-gingerdione, Shoagol, Chloroquine, and 
Hydroxychloroquine had molecular weights in a range of 
194.23D to 335.88D, number of hydrogen acceptor lying in a 
range of 0 to 5, while number of hydrogen donor was scored in a 
scale of 0 to 2. The ligands, Gingerol, Zingerone, Gingerenone, 
1-dehydro,6-gingerdione, Shoagol, and Hydroxychloroquine 
have shown the partition coefficient value of <5 while 
Zingiberene and Chloroquine have shown violation with 
MiLogP, partition coefficient as depicted in Table 1.
 
3.2 In silico Screening
Molecular docking study revealed Zingiberene has the 
highest estimated binding energy score of -6.23 kcal/mol to 
Spike protein of SARS-CoV-2. Chloroquine showed binding 
energy of -5.52 kcal/mol towards ACE2 while Gingerenone 
and Zingiberene have shown binding energy values of -5.87 
and -5.77 kcal/mol respectively. Hydroxychloroquine was 
found to have the binding energy of -6.95 kcal/mol. Shoagol, 
Zingerone and Zingiberene showed higher values of binding 
energy as compared to their agonist Camostat mesylate 
against extracellular domain of Hepsin protein/Serine protease 
TMPRSS2 with the binding energy -5.72 kcal/mol, -5.79 kcal/
mol and -5.52kcal/mol, respectively. The Camostat mesylate 
showed the interaction value of -5.24 kcal/mol. The details 
of the binding energy of each ligand and involved amino acid 
positions in receptor protein are shown in Tables 2, 3 and 4.
 
4. DISCUSSION
ACE2 a trans-membrane protein that diverge from ACE 
in being a carboxypeptidase, is mainly involved in vasodilation 
and thus, is an important target for controlling hypertension37. 
It is majorly expressed in pneumocyte II and, is a main entry 
point for SARSCoV238. The Spike protein of SARS-CoV-2 of 
virus recognises and binds to ACE2 followed by entry of virus 
into the cell. The progression comes into action via extracellular 
domain of cellular protease, Hepsin protein/Serine protease/
TMPRSS2 that split spike protein of SARS-CoV-2 resulting 
in fusion of viral and cellular membrane2. Splitting of Spike 
protein is crucial for SARS-CoV-2 infection. Thus, ACE2, 
spike protein, and Hepsin protein/Serine protease/(TMPRSS2) 
provides insight into viral transmission and reveals therapeutic 
targets. Similar drug targets were used by Wu38, et al., for 
discovery of potential drugs by computational methods by 
considering SARS-CoV-2 spike protein, ACE2, and Hepsin 
protein/Serine protease/TMPRSS2 as the therapeutic targets 
for SARS-CoV-2.
The Lipinski rule of 5 restricted a molecule to be 
developed as an orally active drug candidate with not more 
than one violation of the following four criteria34 
(i) The value of hydrogen bond donors should not be more 
than five, 
(ii) Hydrogen bond acceptors should be under the value of 10, 
(iii) Molecular weight should remain under 500 Da, and 
(iv) Octanol–water partition coefficient should be less than or 
equals to 5. 
A druggable molecule must lie in the range of 5 Lipinski 
rule34. Molecules are considered as poor therapeutic modality, 
if there is > 5 H-bond donors and >10 H-bond acceptors and 
Table 1. Physicochemical properties of phytochemicals in comparison with the marker chemotherapeutic drugs
Ligands
Physicochemical properties
N violation N atoms MilogP<5 MW<500D Noh<10 Nohn<5
Gingerol 0 21 3.22 294.39 4 2
Zingiberene 1 15 5.12 204.36 0 0
Zingerone 0 14 1.52 194.23 3 1
Gingerenone 0 26 3.22 356.42 5 2
1-dehydro,6-gingerdione 0 21 3.06 290.36 4 1
Shoagol 0 20 4.35 276.38 3 1
Chloroquine 1 22 5.00 319.88 3 1
Hydroxychloroquine 0 23 4.00 335.88 4 2
Camostat mesylate 0 29 1.56 398.42 9 4
                         *Shaded values have shown the violation from Lipinski rule of 5
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Table 2. Docking of SARS-CoV-2 Spike ectodomain structure with ligands (Phytochemicals and chemotherapeutic agonist): Binding 
site including hydrogen bond, amino acids and binding energy
Docking Docking complex 
One slant of binding 
Site including 
hydrogen bond
One slant of Binding 
Site including 
hydrogen bond
Amino acids of 
receptor form 
H-bond with ligand
Binding 
energy 
(-kcal/mol)
1. Spike 
protein-
Gingerenone
LyS 733
ASP775
-4.21
2. Spike 
protein-
Zingiberene
ASN856
ASN978
-6.23
3. Spike 
protein- 
Zingerone
ASP775
LEU865
ALA1056
-5.96
4. Spike 
protein – 
Shoagol
LyS733 -3.93
5. Spike 
protein- 1 
Dehydro 
6Gingerdione
CyS391
ILE973
ASP979ARG983
- 6.02
6. Spike 
protein – 
Gingerol
GLy744
SER975
LEU977
ARG1000
-5.16
*Shaded scores are the highest with respect to each case
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Table 3. Docking of ACE2 with ligands (Phytochemicals and chemotherapeutic agonist): Binding site including hydrogen bond, 
amino acids and binding energy
Docking Docking complex 
One slant of binding 
site including 
hydrogen bond
One slant of binding 
site including 
hydrogen bond
Amino acids of 
receptor form 
H-bond with ligand
Binding 
energy
(-kcal/mol)
1. ACE2-Gingerenone LyS562
GLU398
-5.87
2. ACE2-Zingiberene GLN98
GLN102
GLU564
-5.77
3. ACE2-Zingerone GLy205
TyR207
GLU208
ASN210
-4.56
4. ACE2-Shoagol ALA99
LyS562
ARG393
LEU391
-5.22
5. ACE2-1 - Dehydro, 
6- Gingerdione
ARG393
PHE390
ASP350
ALA348
-3.75
6. ACE2-Gingerol HIS493 -2.5
7. ACE2-Chloroquine GLU160 -5.52
8. ACE2-
Hydroxychloroquine
GLU564 -7.16
*Shaded scores are the highest with respect to each case
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Table 4.  Docking of Transmembrane serine protease (TMPRSS2) with ligands (Phytochemicals and chemotherapeutic agonist): 
Binding site including hydrogen bond, Amino acids and Binding Energy
Docking Docking complex 
One slant of binding 
site including 
hydrogen bond
One slant of binding 
site including 
hydrogen bond
Amino acids of 
receptor form 
H-bond with ligand
Binding energy 
(kcal/mol)
1. TMPRSS2-
Gingerenone
LEU112
GLN119
GLy49
ARG52
GLN56
LyS112
-4.73
2. TMPRSS2-
Zingiberene
ARG35
GLN240
GLN254
HIS91
-5.52
3. TMPRSS2- 
Zingerone
ARG85
LEU6
PRO5
-5.79
4. TMPRSS2 – 
Shoagol
HIS9
GLN12
LyS179
LyS230
GLU236
-5.72
5. TMPRSS2 – 
1 Dehydro 
6Gingerdione
ALA103
CyS105
ASP107
ARG110
LyS112
- 4.89
6. TMPRSS2 – 
Gingerol
CyS105
ALA103
SER13
ASP107
ARG208
GLN106
LyS112
-4.99
7. TMPRSS2-
Camostat 
mesylate
ARG52
LyS243
SER246
-5.24
*Shaded scores are the highest with respect to each case
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when the molecular weight is > 500 and calculated partition 
coefficient is greater than 5. As shown in Table 1, the six 
tested phytochemical showing the score within the range 
thus are druggable molecules. The molecules with increasing 
lipophilicity tend to increase its blood brain barrier (bbb) 
permeability and shows druggability34.
Ministry of Ayush, Government of India, has proposed 
Ayurveda’s immunity boosting measures for self care during 
COVID 19 crisis that includes dry ginger (Zingiber officinale) 
as one of the constituents in immunity promoting measures. Z. 
officinale is treasured with medicinal properties that are found to 
be accountable for antibacterial, antioxidant, anti-inflammatory, 
anti-diabetic and anti-tumour effect39. Z. officinale is a spicy 
herb, augmented with the phytochemicals which contributes to 
its medicinal value40. Since ages, ginger has been used to give 
flavour to food and has achieved important position in the list 
of folk remedies against common cold, sore throat etc41.Even 
though, ginger is regarded to be safe, yet its mechanism of 
action is not fully elucidated and a careful evaluation is essential 
before considering its phytochemicals for any therapy42.
COVID-19, the disease the SARS-CoV-2 causes, can spread to 
the lungs, causing pneumonia. Furthermore, ventilator acquired 
pneumonia is a common nosocomial infection in such patients. 
We have earlier reported the antibacterial effect of Zingiber 
officinale against multi-drug resistant strain of P. aeruginosa.
The camostat mesylate was taken as a potent inhibitor of 
TMPRSS2 and reported to block the SARS-2 entry into the 
lung cells43.The molecular docking between ligands and ACE2 
revealed that Gingerenoneone and Zingiberene phytoconstituent 
of Z. officinale has the binding energy value -5.87 kcal/mol 
and -5.77 kcal/mol that lies between the binding energy values 
of Chloroqine (-5.52 kcal/mol) and Hydroxychloroquine 
(-6.95kcal/mol). both the chemotherapeutic marker drugs 
also have in vitro activity against SARS-CoV-2 and may 
possess immunomodulating properties41,42. Mechanisms may 
include ACE2 cellular receptor inhibition, acidification at the 
surface of the cell membrane inhibiting fusion of the virus, and 
immunomodulation of cytokine release41,42. Other mechanisms 
may contain inhibition of viral enzymes such as viral DNA and 
RNA polymerase, viral protein glycosylation, virus assembly, 
new virus particle transport and virus release41,42. We also 
explored the binding of ligands with the extracellular domain 
of serine protease/hepsin/TMPRSS2 by considering the fact 
that these host cellular protease prime Spike protein of SARS-
CoV-2 after viral-host cell attachment to facilitate the viral 
infection. Finding a serine protease inhibitor may block the 
SARS-CoV-2 Zingerone (-5.79 kcal/mol), Shoagol (-5.72 kcal/
mol) and Zingiberene (-5.52 kcal/mol) have shown significantly 
higher binding score as compared to chemotherapeutic 
counterpart, Camostat mesylate (-5.24 kcal/mol). The docking 
results revealed that binding energy value of phytochemicals 
with Spike protein have shown a significant range from -3.93 
kcal/mol to -6.23 kcal/mol, which can be considered as a basis 
for further testing of these phytochemicals against coronavirus. 
Our finding proved that Z.officinale is competent to assail entry 
of the virus due to efficacy of its phytoconstituents to bind viral 
and host protein (schematically depicted in Fig. 1). Further in 
vitro and in vivo studies are warranted including investigations 
to further define the underlying mechanisms.
 
5. CONCLUSION 
The present study shows the inhibitory effect of Z. officinale 
constituents as entry inhibitor of SARS-CoV-2 virus by using 
all the protein of host and virus origin. We found Gingerenone 
and Zingiberene had remarkable effective binding activity with 
ACE2 in terms of docking score compared to Chloroquine. 
Significant quality binding activity against serine protease was 
found with respect to Shoagol, Zingerone and Zingiberene as 
compared with Camostat mesylate. Also, the phytochemicals 
were found to effectively bind with the Spike protein. The 
drug likeliness assessment of all the phytochemicals revealed 
acceptable results with their scores satisfying the Lipinski rule 
of 5.
Z. officinale (Ginger), a natural immunity promoting 
supplements, is a constituent ingredient of a herbal formulation 
recommended by Ministry of Ayush, Government of India, as 
a preventive measure to enhance body’s immunity in the wake 
of COVID-19 outbreak. It is concluded that Z. officinale found 
Figure 1. Interaction of host and viral proteins at entry point the site of action of phytochemicals.
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as entry inhibitor of SARS-CoV-2 in present study, could be a 
safe and reliable adjuvant for mitigating COVID-19 to reduce 
infectivity as it also possesses antibacterial and immunity 
booster activity. While there is no specific prophylactic or 
therapeutic modality against SARS-CoV-2 as of now, our 
study indicated that Z. officinale can be a valuable preventive 
measure for COVID-19. Additional investigations on 
reduction of viral load in experimental models of COVID are 
warranted. The promising outcomes of this study can also be 
further extrapolated to Ginger preparations as muco-adhesive 
mouthwash, gargling agents, throat lozenges, syrups and nasal/
eye drops for the preclusion /mitigation of COVID-19.
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